5 | CONCLUSION
Enhanced knowledge of healthcare providers such as physicians and dentists about bisphosphonates can decrease the incidence of BRONJ and lead to a more favorable recovery.26 Also, improved instruction of patients regarding the use and side effects of bisphosphonates by physicians and dentists can promote the quality of care and decrease the side effects of medical and dental treatments.33 The current results showed that physicians practicing in Tehran had some knowledge about dental considerations in patients taking bisphosphonates; however, their lack of knowledge about some items was obvious.
Authorship:
TP was involved in the conception and design of the work, data collection, drafting of the manuscript, critical revision of the manuscript, and final approval of the version to be published.
ND was involved in the conception and design of the work, data collection, drafting of the manuscript, critical revision of the manuscript, and final approval of the version to be published.
XM was involved in the conception and design of the work, data collection, drafting of the manuscript, critical revision of the manuscript, and final approval of the version to be published.
ACNOWLEDGEMENTS: We wish to thank the physicians who took part in the study.
Conflict of Interest: None declared
Funding Information: No sources of funding are declared for this study.
References
1- Chapurlat RD, Delmas PD, Liens D, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res. 1997; 12(10):1746-1152.
2- Verenna M, Zucchi F, Ghiringhelli D, Binelli L, Bevilacqua M, Bettica P. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. J Rheumatol. 2000; 27(6):1477-1483.
3- Rosenberg TJ, Ruggiero S. Osteonecrosis of the jaws associated with the use of bisphosphnates. J Oral Maxillofac Surg. 2003; 61(8):60-61.
4- Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62(5):527-534. 5- Greenberg MS. Intravenous bis-phosphonates and osteonecrosis. Oral Surg Oral Med Oral Radiol Endod. 2004; 93(3):259-260. 6- Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment, J Oral Maxillofac Surg. 2005; 63(11):1567-1575.
7- Kim JW, Jeong SR, Kim SJ, Kim Y. Perceptions of medical doctors on bisphosphonate-related osteonecrosis of the jaw. BMC Oral Health. 2016; 16(1):92.
8- Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol. 2012; 8:90–96.
9- Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update. J Oral Maxillofac Surg. 2014; 72:1938–1956. 10- Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watt NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015; 30:3–23.
11- Lam DK, Sandor GK, Holmes HI, Evans AW, Clokie CM. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc 2007; 73:417–422.
12- Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479–1491.
13- Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonate: prevalence, risk factors, and clinical characteristics. Clin Ther 2009; 29:1548–1558.
14- Paeng JY. Diagnosis and management of BRONJ (bisphosphonate related osteonecrosis of jaw). J Korean Dent Assoc 2011; 49:378–388. 15- Choi SW, Kim SR, Lee KB. Osteonecrosis of the jaw in a patient with osteoporosis treated with oral bisphosphonates. J Korean Orthop Assoc 2010; 45:151–154.
16- Khan AA, Sandor GK, Dore E. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008; 35(7):1391-1397.
17- Epstein JB, Kish RV, Hallajian L, Sciubba J. Head and neck oral and orophryngeal cancer: a review of medicolegal cases. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 119:177-186.
18- Hristamyan-Cilev MA, Pechalova PP, Raycheva RD, Hristamyan VP, Kevorkyan AK, Stoilova YD. Bisphosphonate-associated osteonecrosis of the jaws: a survey of the level of knowledge of dentists about the risks of bisphosphonate therapy. Folia Med (Plovdiv) 2019; 1; 61(2):303-311.
19- Senturk MF, Cimen E, Tuzuner Oncul AM, Cambazoglu M. Oncologist’s awareness about bisphosphonate related osteonecrosis of the jaws. J Pak Med Assoc 2016; 66(7):880-883.
20- Al-Mohaya MA, Al-Khashan HI, Mishriky AM, Al-Otaibi LM. Physicians’ awareness of bisphosphonates-related osteonecrosis of the jaw. Saudi Med J 2011; (8):830-835.
21- Bauer JS, Beck N, Kiefer J, Stockmann P, Wichmann M, Eitner S. Awareness and education of patients receiving bisphosphonates. J Craniomaxillofac Surg 2012; 40:277-282. 22- Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR. Novel antiangiogenic effects of the bisphosphonate compound zolendronic acid. J Pharmacol Exp Ther 2002; 302:1055-106.
23- Ruggiero SL, Dodson TB, Assael LA, Landsberg R, Mars RE, Mehrotra B. American Association of oral and maxillofacial surgeons’ positions paper on bisphosphonate-related osteonecrosis of the jaws–2009 update. J Oral Maxillofac Surg 2009; 67:2-12.
24- Moinzadeh AT, Shemesh H, Neirynck NA, Aubert C, Wesselink PR. Bisphosphonates and their clinical implications in endodontic therapy. Int Endod J 2013; 46(5):391-398.
25- Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniadaes K. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009; 27:5356-5362. 26- Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carriere P, Dansey R. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bonemetastases. Ann Oncol 2012; 23:1341-1347. 27- Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, Solomayer EF, Wallwiener D, Krimmel M. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 2009; 112:605-609.
28- Dickinson M, Prince HM, Kirsa S, Zannettino A, Gibbs SD, Mileshkin L, OGrady J, Seymour JF, Szer J, Horvath N, Joshua DE. Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Intern Med J 2009; 39:304-316.
29- Kwon YD, KimYR, Choi BJ, Lee DW, Kim DY. Oral bis-phosphonate related osteonecrosis of the jaws: favorable outcome after bisphosphonate holiday. Quintessence Int 2009; 40:277-278.
30- .McLeod NM, Brennan PA, Ruggiero SL. Bisphosphonate osteonecrosis of the jaw: a historical and contemporary review. Surgeon 2012; 10:36-42. 31.Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour S. Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. J Oral Pathol Med 2012; 41:214-221. 32- Patel V, McLeod NM, Rogers SN, Brennan PA. Bisphosphonate osteonecrosis of the jaw–a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention. Br J Oral Maxillofac Surg 2011; 49:251-257.
33- Migliorati CA, Mattos K, Palazzolo MJ. How patients’ lack of knowledge about oral bisphosphonates can interfere with medical and dental care. J Am Dent Assoc 2010; 141(5):562-566